高视医疗附属公司新型人工晶状体植入系统获批医疗器械注册证
5月9日，高视医疗（02407）发布公告，近日公司全资附属公司高视泰靓医疗科技有限公司的“人工晶状体植入系统”已获得由广东省药品监督管理局批准的医疗器械注册证。
该注册证编号为粤械注准20252160605，主要适用于微小切口白内障手术中的人工晶状体植入手术。
与2024年获得批准的人工晶状体植入系统相比，本次获批的系统将手术切口优化至1.8mm以内，能够最大限度减少角膜创伤并加速术后恢复。此外，该产品采用化学接枝润滑涂层技术，实现了晶体推注超低阻力和手术效率的显著提升。该产品为高视泰靓原创设计，并已获得发明专利授权，具备适应不同手术切口大小的能力，同时也能拓展为预装式植入系统，适配市场上所有类型的人工晶状体进行植入手术。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10